Est. 2001·3,000+ placements · six offices · four regions
M&A Activitycurated sourcedetected 2026-08-11 · confidence 95%

Last updated

Boehringer Ingelheim: M&A Activity

Boehringer Ingelheim acquired Evax AG, a Swiss biotech company specializing in equine health, expanding its animal health portfolio.

Source: GNW — Germany

Who
Boehringer Ingelheim · Biotech & Pharma · Switzerland
What happened
Boehringer Ingelheim acquired Evax AG, a Swiss biotech company specializing in equine health, expanding its animal health portfolio.
When
2026-08-11
So what
Consolidation shifts the leadership question from growth to integration.

The leadership read

Consolidation shifts the leadership question from growth to integration. For Boehringer Ingelheim in Biotech & Pharma, the demand moves toward transformation and integration leaders who can merge teams, systems and cultures without losing momentum. Across EMEA, watch whether the integration is properly resourced; deals are won or lost the year after they close.

Market context: This lands while the Talent Market Index reads 95.4 (Cool) — down 5.3 versus the prior month — and EMEA signal share is rising (+5pts).

Boehringer Ingelheim: 3 signals in the last 90 days — above the Biotech & Pharma median of 1 across 31 tracked companies; 0.1% of MitchelLake's Americas signal flow; 8 tracked across 152 days.

MitchelLake in this thematic

Also at Boehringer Ingelheim →

More signals across Biotech & Pharma

M&A Activity · EMEA

Biogen →

Biogen completed acquisition of Apellis Pharmaceuticals, a leader in complement-driven disease treatments

M&A Activity · EMEA

Gilead Sciences →

Gilead Sciences acquired Tubulis, a Germany-based clinical-stage biotechnology company for up to USD 5.0 billion

Leadership Change · EMEA

BioNTech →

BioNTech's Chief Medical Officer Özlem Türeci is described as outgoing, per comments on the Q3 earnings call, as the company reviews its oncology pipeline (T-Pam, pumitamig, gotistobart).

Capital Raising · EMEA

Neobe Therapeutics →

UK biotech Neobe Therapeutics raised $6.8M (£5M) in seed funding led by ARC Ventures, with participation from Faber, Macmillan Ventures, Proven Connect and Empirical Ventures, to advance its NEO22 engineered-bacteria cancer program toward an IND filing in 2028.

Leadership Change · EMEA

Harbour BioMed →

Harbour BioMed (HKEX: 02142) appointed Vivian Feng as Head of External Collaboration, a new senior role overseeing partnerships with external parties.

Capital Raising · EMEA

mbiomics →

mbiomics secured a further €12M, bringing its Series A to €30M to advance microbiome-based therapeutics (as reported in a roundup of European biotech financings).

Where this lands in our work

Weekly briefing

Track companies like Boehringer Ingelheim — with our analysis

Anyone can set an alert for one company. We send a weekly read on the whole peer set — who's moving, and what it means for leadership. Pick what to follow:

Intelligence powered by Autonodal ↗

Nearby in the record